Galectin Therapeutics Inc. (GALT) Expected to Post Earnings of -$0.14 Per Share
Equities analysts expect that Galectin Therapeutics Inc. (NASDAQ:GALT) will announce earnings per share of ($0.14) for the current quarter, Zacks reports. Zero analysts have issued estimates for Galectin Therapeutics’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.17). Galectin Therapeutics reported earnings of ($0.11) per share in the same quarter last year, which would indicate a negative year over year growth rate of 27.3%. The firm is expected to announce its next earnings report on Tuesday, August 13th.
On average, analysts expect that Galectin Therapeutics will report full year earnings of ($0.58) per share for the current year, with EPS estimates ranging from ($0.74) to ($0.42). For the next year, analysts forecast that the business will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.58) to ($0.52). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08).
Galectin Therapeutics stock traded down $0.03 during trading hours on Wednesday, reaching $4.70. 1,998 shares of the stock were exchanged, compared to its average volume of 401,092. The company has a market capitalization of $212.01 million, a price-to-earnings ratio of -12.37 and a beta of 3.54. Galectin Therapeutics has a twelve month low of $3.17 and a twelve month high of $9.49.
In related news, Director Richard E. Uihlein purchased 20,700 shares of Galectin Therapeutics stock in a transaction dated Tuesday, April 9th. The shares were bought at an average cost of $4.82 per share, for a total transaction of $99,774.00. Following the purchase, the director now owns 2,628,489 shares in the company, valued at approximately $12,669,316.98. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Marc Rubin sold 51,185 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $6.02, for a total transaction of $308,133.70. Following the completion of the sale, the director now owns 13,581 shares in the company, valued at $81,757.62. The disclosure for this sale can be found here. Company insiders own 45.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Galectin Therapeutics by 3.3% in the 1st quarter. Northern Trust Corp now owns 89,771 shares of the company’s stock valued at $458,000 after purchasing an additional 2,839 shares in the last quarter. Citigroup Inc. bought a new position in Galectin Therapeutics in the 1st quarter valued at approximately $298,000. Advisor Group Inc. raised its holdings in Galectin Therapeutics by 2.7% in the 1st quarter. Advisor Group Inc. now owns 692,589 shares of the company’s stock valued at $3,539,000 after buying an additional 18,298 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Galectin Therapeutics in the 1st quarter valued at approximately $900,000. Finally, Laurion Capital Management LP raised its holdings in Galectin Therapeutics by 81.7% in the 1st quarter. Laurion Capital Management LP now owns 171,543 shares of the company’s stock valued at $877,000 after buying an additional 77,145 shares during the last quarter. Institutional investors own 12.68% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Read More: What is a front-end load?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.